CancerVisit

💡 Cancer doesn’t recognize borders—neither should knowledge. Grateful to launch a global oncology news platform with @oncodaily through @MedNewsWeek —uniting physicians, researchers, pharma leaders, and patients around one shared mission. One platform. Global voices. Faster

💡 18 years ago, I met Dr. Lawrence Einhorn. My 1st mentor. He is an elite clinician. Trial pioneer. Exceptional human. At @ASCO #GU26 we had our annual @OncLive Fellows Forum. ⭐️Loved hearing the trainees present their cancer research and the impact their mentors had on

RT @CParkMD: ✌️ PEACE-3 is a true OS-positive trial. Enzalutamide + radium-223 beats enzalutamide alone in bone-dominant mCRPC. ✅ HR 0.76…

⭐️Progress in oncology is built in moments of shared curiosity. Dinner meeting with Oliver Sartor @sartor_oliver my VISION co-PI and pioneer of PSMA radioligand therapy, discussing how Lutetium-177 is becoming the Model T of radioligand therapy — the first scalable platform for precision systemic radiation in prostate cancer ⚛️🚀 Walking back, we ran into Jonathan Rosenberg (@DrRosenbergMSK ), my EV-301 co-PI and global leader in antibody–drug conjugate development, he discussed Enfortumab vedotin, KEYNOTE-B15, and the convergence of targeted payload therapies 🎯 Not different drugs. Different chapters of the same scientific story 📖 Radioligands. Antibody–drug conjugates. Precision targeting is reshaping cancer therapy 🌍 The future of oncology will be written in better precision development — and in the patients who benefit from it. Where do you think precision oncology goes next? @tompowles1 @DrChoueiri @neerajaiims @PGrivasMDPhD @montypal @shilpaonc @DrYukselUrun @crisbergerot @alantanmd @Stefani19753108 @arnabguonc @Dr_Aggen #serendipity ✨ #GU26 @ASCO @urotoday @oncodaily @OncLive

Thank you @DrDanielHeng for stopping by our @ASCO #GU26 poster sessions to review the oncology trainees research and offer career advice. Everyone was very appreciative of your time. @KalantriShreyas @JeffreyYZhong @caseccc @abbylgrier @AJangMD @PBarataMD @JasonBrownMDPhD @HemOncFellows @DrYukselUrun @yekeduz_emre @crisbergerot @NazliDizman @PauloBergerot @Stefani19753108 @nataliagandur @urotoday @oncodaily @OncLive

⭐️ The future of bladder cancer is smarter treatment for our patients. Data from KEYNOTE-B15, RETAIN, and NIAGARA at @ASCO #GU26 move us closer to rational, precision bladder preservation. ctDNA + urine tumor DNA + tumor genomics + clinical response may help identify who needs more treatment — and who can safely preserve their bladder. #BladderCancer @BladderCancerUS @WorldBladderCan @oncodaily @urotoday @OncLive

⭐️Follow along today as @CParkMD of @Norton_Health and Advisory Dean/Clinical Professor at @uofl takes us along at @ASCO #GU26 .

💰 slide of POSEIDON by Dr. Bridget Koontz @bridget_koontz @AmarUKishan @DrSpratticus Full manuscript JUST RELEASED👇 thelancet.com/journals/lance… @DrChoueiri @yekeduz_emre @DrYukselUrun @crisbergerot @Silke_Gillessen @neerajaiims @urotoday @brunolarvol @OncLive

Opportunistic salpingectomy can prevent ovarian cancer!

Our immune system is the driver of the biologic process of aging. A new and comprehensive review @NatRevImmunol nature.com/articles/s4157…

🫁 Adjuvant Durvalumab in Resected NSCLC (BR.31). Primary population: EGFR–/ALK–, PD-L1 ≥25%. Median follow-up 60 mo. No DFS benefit: HR 0.93 (95% CI 0.71–1.25), P = .64. No benefit across hierarchical subgroups. Grade 3–4 AEs: 26% vs 20%. Adjuvant durvalumab did not improve DFS, regardless of PD-L1. 📖 @JCO_ASCO DOI 👉🏻 10.1200/JCO-25-01828 #CánCare #NSCLC #lcsm #immunotherapy #thoraciconcology

If u r NOT joining asco GU 2026 in person, Don't worry . U can join us 🙂 for this global academic webinar on ASCO GU 2026 updates on 3rd March 2026. @DrYukselUrun @HHammersMD @dmukherji @nataliagandur Link for Registration 👇 us02web.zoom.us/webinar/regist…

#DICIPLE: 4-year 6-month vs continuation Nivo+Ipi in mNSCLC ◼️ PFS: 18.7m vs NR ◼️ OS: 55.5m vs NR ◼️ 18m OS: 80.6% vs 93.8% ◼️ Grade 3-5 irAEs: 54% → 24% ◼️ QoL: 15.5m vs NR (HR=0.36) 🛑 at 6 months = same survival, less toxicity @JTOonline @OncoAlert pubmed.ncbi.nlm.nih.gov/41690366/

Real-world analysis: maintenance pemetrexed did not meaningfully change OS ▫️1L maintenance pemetrexed: 19.5 mo (17.5–21.6) ▫️No 1L maintenance pemetrexed: 18.6 mo (15.6–23.0)

Algorithm of ET ± targeted treatment options after ET + CDK4/6 inhibitors. Some options are not yet approved— caution! From Dr. Alessandra Gennari’s excellent discussion at #ESMO25👇

DESTINY-Breast09 6 Facts that may surprise you The story isn’t that simple. Longer PFS than CLEOPATRA, strict stats, ~30 cycles of ADC, ILD context, pertuzumab question, CNS data pending. Game-changing? #BreastCancer #HER2 #Oncology#MVOnco

Data from global sotorasib expanded access programs @JTOonline in KRAS G12C NSCLC (n=268). Real world PFS 6.3m, OS 9.5m, similar in PS 0-1 vs 2 and +/- brain metastases. 58% of PS2 improved to PS 0-1 after 1 cycle. Most common TRAE was diarrhea at 31%. jtocrr.org/article/S2666-…

Statin Side Effects & The "Nocebo" Effect A massive review of randomized trials found most side effects attributed to statins (memory, sleep, mood) occur just as often in placebo groups! #science #evidence @TheLancet

The same applies in bladder cancer. Pathological complete response is only a potential surrogate for the effect of neoadjuvant systemic therapy on the micro-metastatic disease which is not yet radiologically visible. ctDNA tells us what’s actually happening in those

BOSABCS West. My fabulous colleague @irenekangmd helps us place novel endocrine/targeted therapies into our clinical practice. @cityofhope @SABCSSanAntonio @OncoAlert